LON: REDX 56.50GBX

Redx Pharma Announces Phase 2 Dose Selection of its Porcupine Inhibitor, RXC004 Exercise of Options and Total Voting Rights Redx to Receive Milestone Payment of $4 million for RXC006

About us
Our pipeline
Our science
- Our scientific publications
Investors
News & events
- News & events
Contact us
- Contact us
- Careers

About us
Our pipeline
Our science
- Our scientific publications
Investors
News & Events
- News & events
Contact
- Contact us
- Careers

Top suggestions

Redx Pharma Announces Phase 2 Dose Selection of its Porcupine Inhibitor, RXC004
Exercise of Options and Total Voting Rights
Redx to Receive Milestone Payment of $4 million for RXC006

Presentations, analyst reports,
documents & videos

Corporate Presentations

Analyst reports

Documents

Videos and webcasts

News & events

Our scientific publications

Investor centre

Contact us

RSS

Request e-mail alerts Register

Copyright © 2021 Redx Pharma Plc

Privacy policy
Cookie policy

Website design & build by Carr Kamasa Design

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we'll assume that you are happy to receive all cookies. Cookie Policy.